May 24, 2017
Cleveland, Ohio, USA –May 24, 2017 – Harrington Discovery Institute at University Hospitals in Cleveland, Ohio – part of The Harrington Project for Discovery & Development – is pleased to announce its request for proposals for the Harrington Rare Disease Scholar Award. The Harrington Rare Disease Scholar Award supports breakthrough research for therapeutic discoveries in rare diseases. The program is sponsored by Takeda Pharmaceutical Company Limited (TSE: 4502) and overseen by Harrington Discovery Institute, a nonprofit initiative that helps academic researchers translate their most promising inventions into new medicines.
“We are excited to launch this new program with Takeda,” said Jonathan S. Stamler, MD, President, Harrington Discovery Institute and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at University Hospitals and Case Western Reserve University School of Medicine. “The Harrington Rare Disease Scholar Award provides a unique opportunity to advance cutting-edge research in rare diseases into life-saving treatments.”
Harrington Rare Disease Scholars will receive:
Letters of Intent are being accepted through July 19, 2017
Harrington Discovery Institute will select up to 10 researchers to receive the Harrington Rare Disease Scholar Award. Scholars will work closely with drug development experts from its Innovation Support Center, which provides hands-on industry guidance not found in traditional academic research settings. Harrington Rare Disease Scholars and their institutions retain the intellectual property rights to their work.
The award is open to MD and PhD researchers at accredited academic medical centers, research institutions, and universities in the United States. Selection criteria include innovation, creativity and potential for impact on human health. Award recipients will be selected by Harrington Discovery Institute’s Scientific Advisory Board for Rare Diseases and announced in early 2018.